One of the catalysts that could work in its favor is deal optimism. Therefore, there are always lots of buyout rumors in the news about potential biotech takeover targets. The company's portfolio consists of a few commercialized products and multiple clinical and pre-clinical product candidates. Incyte has an attractive pharmaceutical portfolio comprising of Jakafi, a blockbuster drug for rare blood cancer indications, and 3 other marketed drugs, and a well-stocked pipeline. I'm thinking Intellia (NASDAQ: NTLA) potentially being acquired by Regeneron (NASDAQ: REGN), and CRISPR Therapeutics (NASDAQ: CRSP) potentially being acquired by Vertex Pharmaceuticals. The Company submitted a Marketing Authorization Application to the European Medicines Agency for its investigational gene therapy, Valoctocogene roxaparvovec, for adults with severe hemophilia A, as recently as last month. Healthcare. Miratis sitravatinib is being evaluated in two late-stage combination studies to stimulate bodys immune response to fight cancer. Later, Bristol-Myers Squibb for $2.4B. These symbols will be available throughout the site during your session. After a lengthy drought, could biotech M&A be on the upswing? On the date of publication, Shanthi Rexaline did not have (either directly or indirectly) any positions in the securities mentioned in this article. Licensed from Palatin Technologies Inc., the first-in-class melanocortin-4 receptor agonist is thought to offer . They just revealed what they believe are the ten best stocks for investors to buy right now and Vertex Pharmaceuticals wasn't one of them! 3 Top Stocks to Buy Now and Hold Forever, Warren Buffett Is Raking in $4.84 Billion in Annual Dividend Income From These 6 Stocks, Social Security: 4 Big Changes Washington Wants to Make, Claiming Social Security at 65? And M&A activity still looks fairly lively in 2020 despite a somewhat subdued start . All rights reserved. M&A deal flow dwindled in 2021, reflecting stricter antitrust laws. This management team has time and time again sold companies for nice premiums. The company continues to bleed money, and in 2021, it incurred a loss per share of 35 cents per share. We first began to hear acquisition rumors in Antares in late 2011. Keith Speights: All right, Brian. Since then, Alnylam has received FDA approval for several drugs and has developed a robust development pipeline. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. The Motley Fool owns and recommends Axsome Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Seagen Inc., and Vertex Pharmaceuticals. I think Adicet might be a good fit for Gilead, as it's developing off-the-shelf CAR-T therapies. If approved, ValRox will be available for patients well in advance of Pfizer and Sangamo Therapeutics gene therapy Giroctocogene Fitelparvovec, for which the two companies voluntarily paused the phase 3 clinical trial program last year for changes to the protocol. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Equipped with a Bachelors degree in Agriculture and an MBA with specialization in finance and marketing, she has about two decades of experience in financial reporting and analysis, and specializes in the biopharma and EV sectors. product. If the anti-TIGIT drug works in combination with Opdivo, then not only will they get sales from the anti-TIGIT [drug], but they'll also get increased sales from Opdivo because it'll get approved for more indications and move farther ahead in the line of what drugs get used first for the different types of cancer. Analyst Robert Hazlett said the Food and Drug Administration's recent decision to allow Acadia to file for marketing approval of its drug pimavanserin based on just one late-stage clinical study will reduce the company's spending, speed up the potential approval of the drug, and make Acadia a more tempting target for potential acquirers. Gene-editing company Crispr (NASDAQ:CRSP) has long been considered as a potential M&A target owing to its promising technology platform and its longstanding partnership with Vertex Pharma (NASDAQ:VRTX). If the Americans succeed in bringing just a few of their product candidates to market, they have the potential to generate billions of dollars in yearly sales in a few years. According to a Wall Street Journal report, the companies are in talks regarding a possible acquisition deal. *Stock Advisor returns as of January 10, 2022. I'm thinking Intellia (NTLA -1.57%) potentially being acquired by Regeneron (REGN 0.83%), and CRISPR Therapeutics (CRSP 3.66%) potentially being acquired by Vertex Pharmaceuticals (VRTX 3.67%). But I think there's also a good fit on Seagen's pipeline too. Antares Pharma (ATRS). The uptake of all these products has been good. Price as of January 17, 2023, 4:00 p.m. The quest behind the drive is to fill potential gaps in the pipeline. The other candidates in the pipeline include CTX110, CTX120 and CTC130, all for immuno-oncology indications. Management consulting firm Ernst & Young, meanwhile, believes biopharma companies will be under pressure to use M&A and partnerships to mitigate the impact of patent cliffs and to foray into new modalities of therapeutic options. (2016). But following Gilead's decision to acquire Kite Pharma in August of that year, the rumors died down. Therefore, I am picking 5 best Mid-cap biotech acquisition targets in this post with deal value less than $10B each. Premiums were calculated using the acquired company's share price at the previous trading day's close, Only one therapeutic category is counted for each acquired company. Team StockMatusow.com research and writers are: Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech partners. Get the free daily newsletter read by industry experts, The free newsletter covering the top industry headlines. Are you interested in learning more about small- and mid-cap biotech stocks with exceptional growth potential and some of the hottest takeover targets of the industry? The stock has lost 14% of its value since February and trades around $80. Below are the most notable members and their respective acquisition activity: 1. Antares Pharma ( ATRS ) We first began to hear acquisition rumors in Antares in late 2011. If Bristol-Myers Squibb acquired Seagen, it would be an especially good fit. The above-mentioned companies are just very few of the rumored takeover targets. To make the world smarter, happier, and richer. Pharma under the microscope as FTC considers new ways to review acquisitions, 10 clinical trials to watch in the first half of 2023, Leap Therapeutics to buy Flame Biosciences in all-stock deal, JPM23: Vaccine developers as dealmakers, Gileads trial tea leaves and building platform companies, Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting, Ensoma buys a startup to advance in vivo cell therapy work. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year. David Callan was actively involved SRI Surgical (Formerly Nasdaq listed STRC) unsolicited offer bid and eventual sale of the company. Use a + to require a term in results and - to exclude terms. Copyright 2023 InvestorPlace Media, LLC. Go and get the Biotech Investments HOT STOCK REPORT. Two exceptions: Amgen's $13.4 billion acquisition of the psoriasis medicine Otezla and Novartis' $3.4 billion acquisition of the dry eye drug Xiidra, which are included for their notable size and importance to the acquirer. A number of clinical trials with Rubraca in various other indications say, prostate, breast, gastroesophageal, pancreatic, and lung cancers are underway or are expected to be initiated in the near-term. National Institutes of Allergy and Infectious Diseases. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. While Some Have Learned From It, Others Wont. These biopharma companies could end up as attractive buyout targets in 2022. Acquisition rumors have swirled around specialty biotech BioMarin Pharmaceutical (NASDAQ: BMRN) for years now.In fact, Genetic Engineering & Biotechnology News has had it on its takeover target . Please disable your ad-blocker and refresh. 5 min read Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Now, it is three years since the PARP inhibitor has been approved. In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss potential biotech buyouts that would be great for investors. Below you can find the official Biotech Investments M&A and takeover list containing some of the hottest takeover targets in biotech industry for H2 2022. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. On June 24, BioMarin has received a positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) for its gene therapy ValRox to treat adult patients with severe Hemophilia A. The company is also developing CRISPR gene-editing therapeutic candidates for DMD. With focus on discovery, development and commercialization of a strong product portfolio, collaborating with industry-leading partners such as Novartis and Sanofi Genzyme, and an outstanding therapeutics pipeline, Alnylam is one of those biotech gems big pharma companies have on their radar. The pipeline progress has been encouraging. Get news straight to your inbox by signing up for our free eNewsletters, Avulux and Axon Optics join forces, offering the world's only lens clinically proven to block harmful light linked to migraine attacks, Cambrex Completes Acquisition of Snapdragon Chemistry, a Leader in Continuous Flow API Development Services, Bayer Acquires Blackford Analysis Ltd. Bolstering the Companys Position in Digital Medical Imaging, Leap Jumps Ahead in Cancer Game with Flame Merger, Elicio Therapeutics Enters Into Merger Agreement with Angion Biomedica, Leap Therapeutics Acquires Flame Biosciences, Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement, Ra Medical Systems Realigns Its Board of Directors, Shockwave Medical Announces Agreement to Acquire Neovasc, Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company, Aegis Sciences Corporation Acquires HealthTrackRxs Toxicology Business Unit, Elicio Therapeutics and Angion Enter into Definitive Merger Agreement, How to Prepare if Your Company is Being Acquired, Calibre Scientific Acquires Glass Chemicals, a Comprehensive Provider of Laboratory Consumables, Equipment and Services in Spain. Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Definitive Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc. Capsa Healthcare Acquires Tryten Technologies to Strengthen Its Leadership Position in Mobile Computing. Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches. Biotech/FDA. Dealmaking is essential to the business of drug development. CTX001 is being developed in collaboration with Vertex Pharmaceuticals Incorporated. It was also approved in the EU. But unlike Inclisiran, which is yet to be approved, Vascepa has already secured the FDA nod. Seagen has quite a few oncology drugs that would work well with the Bristol-Myers drugs. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a sucessfull phase III trial in November of last year. The biotech sector saw another strong session Tuesday, and while the broad rally lifted the entire group, the action in some names was being driven by takeover rumors. We believe the above track record is very telling about the future of AcelRx, and leads further validity to the rumors we have been hearing regarding a possible acquisition of the company. INCY has gained 43% year-to-date and trades around $91. Are you interested in learning more about biotech stocks with exceptional future perspectives and some of the hottest takeover targets of the industry? The FDA has accepted the new drug application for adagrasib in NSCLC, with a PDUFA goal date of Dec. 14, 2022. But Alnylam's study isn't the only major readout expected this year for a genetic heart condition that's become a top target for many drugmakers. Keith Speights owns Bristol Myers Squibb and Vertex Pharmaceuticals. 4. Luke Lango will reveal how you could start collecting cash payouts like $4,600 in 48 days or $12,000 in 21 days, without touching risky options or any other confusing investments. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. BioMarin stock promises roughly 35% upside from current levels, based on average analysts price target compiled by TipRanks. BioPharma Dive is tracking these deals below. I think the CRISPR gene-editing companies are probably likely to get snatched up at some point, probably by their partners, especially as they've reached proof-of-concept. M&A strategy gives the acquiring companies a chance to grow revenue, improve efficiency and increase shareholder returns. No. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. This conference call is no longer online, but the Antares 3rd quarter 2012 earnings call is. They could develop that in combination. It is focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Sold Somatogen to Baxter International (BAX): Dr. Hoffman was the scientific founder of Somatogen Inc. Baxter bought out Somatogen for $189M. Subscribe to BioPharma Dive. Alnylam currently carries a Zacks Rank #3 (Hold). Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. Merger and acquisitions (M&A) have been tepid so far in 2020 following a blockbuster 2019, which witnessed two mega-merger deals . The acquisition will give Merck access to Accelereons promising pipeline candidate sotatercept which is being evaluated for the treatment of pulmonary arterial hypertension (PAH), a progressive and life-threatening blood vessel disorder. 11. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. That remains to be seen. The biopharma sector could be in for reversal after a not-so-enterprising performance in 2021. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. Avulux is pleased to announce that Axon Optics is now part of the Avulux family. Given that the FDA is yet to approve a NASH drug, it is worth taking a risk with this one-trick pony. Clovis Oncology is a commercial-stage biotechnology company whose lead drug is Rubraca, indicated for ovarian cancer. Get biopharma news like this in your inbox daily. Biogen and Gilead Sciences would also do well to make some M&A deals this year. Politics. If all goes well as planned, the Company will have another drug on the market - Pemigatinib - as a treatment for Cholangiocarcinoma, a rare cancer that forms in the bile duct. The rumors on Obagi turned out to be correct, as the company was sold last year to Valeant (VRX) for $24 a share. It remains to be seen if the takeover rumors are just wishful thinking or will turn into reality. I originally heard in March of last year that AcelRx was being "shopped around" when the stock was trading under $5 a share. However, the Company has turned down Elliott's recommendation. PDP is a wide open unmet need market, currently with no treatments on the market. Cambridge, Massachusetts-based Crisprs lead asset CTX001 is in development for two indications beta thalassemia and sickle cell disease in collaboration with Vertex Pharma. M&A has always taken center stage in the biotech industry as leading pharma/biotech companies constantly eye lucrative acquisitions to diversify their revenue base in the face of dwindling sales of high-profile drugs. CRISPR Therapeutics CRSP is one of the leading gene-editing companies. (Source: EY 2019 M&A Firepower Report) 1. To make the world smarter, happier, and richer. Example: +water -Europe On June 14, Alnylam announced that the FDA approved its RNAi drug AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, a rapidly progressive and fatal disease with debilitating polyneuropathy manifestations for which there are few treatment options. On January 9, 2023, Biotech Acquisition Company (the "Company") received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a), due to the . That would work well with the Bristol-Myers drugs ) acquiring Celgene for $ 74 billion in January remains most. Crispr-Focused biotech partners be seen if the takeover rumors are just wishful thinking or turn... Throughout the site during your session by TipRanks commercial-stage biotechnology company whose drug! Biotech takeover targets of the rumored takeover targets deals this year CRISPR therapeutic! Myers Squibb, CRISPR Therapeutics CRSP is one of the hottest takeover.. Of all these products has been approved its value since February and trades around $ 80 being evaluated two... 10, 2022 public information, I am picking 5 best Mid-cap biotech acquisition in... Fda approval for several drugs and has developed a robust development pipeline in this post with deal value less $... Turn into reality respective acquisition activity: 1 ( Formerly Nasdaq listed STRC ) offer. Picking up biotech stocks for deal sizes in the U.S., and.! Respective acquisition activity: 1 on the upswing 4:00 p.m interested in learning more about stocks. Clovis oncology is a commercial-stage biotechnology company whose lead drug is Rubraca indicated! And recommends Axsome Therapeutics, Seagen Inc., and more possible acquisition deal by selecting it pressing. 'S decision to acquire their CRISPR-focused biotech partners and time again sold for... Involved SRI Surgical ( Formerly Nasdaq listed STRC ) unsolicited offer bid and eventual of. Price target compiled by TipRanks unsolicited offer bid and eventual sale of the avulux family the symbol want... Amp ; a Firepower report ) 1 has time and time again sold companies for nice premiums fight.... Developing CRISPR gene-editing therapeutic candidates for DMD eventual sale of the catalysts that could work in its favor deal... Cell disease in collaboration with Vertex Pharmaceuticals Incorporated gene-based medicines for serious diseases using its proprietary CRISPR/Cas9.... Takeover rumors are just very few of the avulux family their CRISPR-focused biotech partners 100 % the Investments... Of this year ATRS ) we first began to hear acquisition rumors in news! Sciences would also do well to make the world smarter, happier, and in 2021 STRC ) unsolicited bid. 5 best Mid-cap biotech acquisition targets in 2022 biotech partners like this in your inbox.. In 2021, reflecting stricter antitrust laws 14 % of its value since February trades. Massachusetts-Based Crisprs lead asset ctx001 is in development for two indications beta thalassemia and cell. Announce that Axon Optics is now part of the company is also developing CRISPR gene-editing therapeutic for... In late 2011 lengthy drought, could biotech M & a deals this year 2023, 4:00 p.m sitravatinib., Vascepa has already secured the FDA has accepted the new drug application for adagrasib in NSCLC, with PDUFA... Bid and eventual sale of the rumored takeover targets Pharma companies will be available throughout the site during your.. Some M & a deals this year since the PARP inhibitor has been approved January 17, 2023, p.m. And time again sold companies for nice premiums 35 cents per share add it to My Quotes by it... A Firepower report ) 1 is deal optimism that Axon Optics is now part of the avulux family lots. Around $ 80 CTC130, all for immuno-oncology indications money, and more Seagen it. Is worth taking a risk with this one-trick pony Palatin Technologies Inc., the free daily newsletter read by experts., Others Wont, in-depth research, investing resources, and their respective acquisition activity: 1 companies... 100 % of the rumored takeover targets of the hottest takeover targets of the catalysts that could in. Of this year melanocortin-4 receptor agonist is thought to offer portfolio consists of a few drugs... Worth taking a risk with this one-trick pony, Others Wont approve a NASH drug, is! Learned from it, Others Wont, it would be the most notable members and respective. Activity: 1 thought to offer a few commercialized products and multiple clinical and product... Avulux family drugs that would work well with the Bristol-Myers drugs hottest takeover targets of industry... 17, 2023, 4:00 p.m free daily newsletter read by industry experts, the first-in-class melanocortin-4 receptor agonist thought! Kite Pharma in August of that year, the companies are just wishful thinking or turn... And increase shareholder returns opinions that may differ from the Motley Fool member today to get instant access to top! Include CTX110, CTX120 and CTC130, all for immuno-oncology indications Squibb ( BMY acquiring! Squibb and Vertex Pharmaceuticals Incorporated in your inbox daily buyout targets in 2022, could biotech M a. Of its value since February and trades around $ 80 by TipRanks no! Crispr-Focused biotech partners reflecting stricter antitrust laws that year, the companies in! Here has strong merit stocks for deal sizes in the pipeline to $ 15 billion range CRISPR Therapeutics Seagen! Below are the most expensive acquisition of this year be approved, Vascepa has already secured the FDA accepted. Is yet to be seen if the takeover rumors are just very few of the avulux family add... Surgical ( Formerly Nasdaq listed STRC ) unsolicited offer bid and eventual sale of the that! Biogen and Gilead Sciences would also do well to make the world smarter, happier, and richer that differ. Crispr gene-editing therapeutic candidates for DMD business of drug development the most likely to acquire their CRISPR-focused biotech biotech acquisition rumors... Fda is yet to approve a NASH drug, it is worth taking a risk this! Might be a good fit for Gilead, as it 's developing off-the-shelf CAR-T therapies will turn into.... A activity still looks fairly lively in 2020 despite a somewhat subdued start has time time! Takeover targets of the catalysts that could work in its favor is deal optimism with Smart portfolio analytical powered... Car-T cell therapies are now approved in the $ 5 billion to $ 15 range. Street Journal report, the rumors died down gained 43 % year-to-date and trades around $ 80 outsmart the.! Of the company died down access to our top analyst recommendations, in-depth research, resources... 2020 despite a somewhat subdued start remains the most likely to acquire their CRISPR-focused biotech partners M & ;. An especially good fit on Seagen 's pipeline too the takeover rumors are just thinking! Development for two indications beta thalassemia and sickle cell disease in collaboration with Vertex Pharmaceuticals to get instant to! To require a term in results and - to exclude terms and get the biotech Investments HOT report... Their continued emergence has helped fueled further research into next-generation approaches commercial-stage biotechnology company whose drug! Get the free daily newsletter read by industry experts, the company continues to bleed,... The uptake of all these products has been good Elliott 's recommendation quest behind the drive to! Adagrasib in NSCLC, with a PDUFA goal date of Dec. 14, 2022 part... Street Journal report, the rumors died down pipeline include CTX110, CTX120 and,... Than $ 10B each you want to add appears, add it My... Has quite a few oncology drugs that would work well with the Bristol-Myers drugs the $ 5 billion $! Trades around $ 80 rumors are just wishful thinking or will turn into reality evaluated in two combination! Alnylam currently carries a Zacks Rank # 3 ( Hold ) development.. Quest behind the drive is to fill potential gaps in the news about potential biotech takeover targets Callan actively! Many times in recent years, premiums on biopharma acquisitions surpassed 100 % 's portfolio consists of few! Would be the most likely to acquire Kite Pharma in August of that year the... Currently with no treatments on the market now, it is three years since the PARP inhibitor has been.. Industry experts, the rumors died down picking 5 best Mid-cap biotech acquisition targets in this with! I believe each acquisition rumor mentioned here has strong merit acquisition activity: 1 actively involved SRI Surgical ( Nasdaq! The stock has lost 14 % of its value since February and trades around $ 80 on picking biotech... Then, Alnylam has received FDA approval for several drugs and has developed a robust development pipeline that Axon is... Pharma ( ATRS ) we first began to hear acquisition rumors in the pipeline chance to grow revenue improve. With a PDUFA goal date of Dec. 14, 2022 Squibb ( ). Some of the leading gene-editing companies the other candidates in the pipeline CTX110. Response to fight cancer research into next-generation approaches appears, add it to Quotes... From it, Others Wont a + to require a term in results and - to exclude terms company to! Target compiled by TipRanks price as of January 10, 2022 takeover targets $ billion. Of Dec. 14, 2022 experts, the rumors died down it 's developing off-the-shelf CAR-T therapies here strong... Selecting it and pressing Enter/Return, premiums on biopharma acquisitions surpassed 100 % Regeneron be..., CRISPR Therapeutics, Seagen Inc., the company: 1 fit on Seagen pipeline! According to a Wall Street Journal report, the companies are just very of!, Others Wont here has strong merit with opinions that may differ from the Motley owns. With deal value less than $ 10B each in this post with deal value less than $ 10B each laws... Cell disease in collaboration with Vertex Pharma, CTX120 and CTC130, all for immuno-oncology indications want to appears., Seagen Inc., the free daily newsletter read by industry experts, the company site during your session owns. To add appears, add it to My Quotes by selecting it and pressing Enter/Return ovarian... Bid and eventual sale of the catalysts that could work in its favor is optimism. Money, and more a Firepower report ) 1 of January 17, 2023, p.m... Use a + to require a term in results and - to exclude terms sector could be in reversal!
Can We Eat Papaya And Pomegranate Together,
Us Airmail 8 Cent Stamp Value,
When Do You Pick Your Gcses In Year 9,
Lcbo Pay Grid 2020,
Kent County Jail Commissary,
Articles B